Business Context and Reporting Period
Company: Translational Development Acquisition Corp. (TDAC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2025
Status: Cayman Islands special purpose acquisition company (SPAC) incorporated in April 2022. The Company consummated its Initial Public Offering (IPO) on December 24, 2024, and is currently searching for a target business combination. It has not commenced any operating activities.
Key Financial Metrics
| Metric | Value (Q1 2025) | Value (Q4 2024) |
|---|---|---|
| Net Income | $1,483,074 | Not applicable (IPO closed Dec 2024) |
| Revenue | $0 | $0 |
| General & Administrative Costs | $347,408 | $0 |
| Trust Account Balance | $176,180,828 | $174,350,346 |
| Cash (Outside Trust) | $206,600 | $438,174 |
| Working Capital | $92,522 | $439,930 |
| Total Liabilities | $6,360,400 | $6,247,803 |
| Deferred Underwriting Fee | $6,037,500 | $6,037,500 |
Income Source: Net income was driven entirely by dividends earned on marketable securities held in the Trust Account ($1,830,482), offset by operating expenses.
Material Changes vs. Prior Period
- Trust Account Growth: The Trust Account increased by approximately $1.83 million due to dividends earned on U.S. Treasury securities and money market funds. The per-share redemption value rose from $10.11 (Dec 31, 2024) to $10.21 (Mar 31, 2025).
- Cash Burn: Cash held outside the Trust Account decreased by $231,574, reflecting net cash used in operating activities. This decline is attributed to general and administrative costs, including a $30,000 administrative fee to the Sponsor and $60,850 in consulting fees.
- Liabilities: Current liabilities increased primarily due to accrued offering costs and accounts payable. The "Due to Sponsor" balance increased to $22,423.
- Share Structure: As of March 31, 2025, there were 17,250,000 Class A ordinary shares subject to possible redemption and 4,657,500 Class B ordinary shares (Founder Shares) outstanding.
Outlook, Risks, and Contingencies
- Going Concern: Management has determined that the liquidity issue raises substantial doubt about the Company's ability to continue as a going concern for one year from the date of issuance. Current cash outside the Trust ($206,600) may be insufficient to sustain operations while searching for a target.
- Extension of Time: The Company must complete a Business Combination within 18 months of the IPO (by June 24, 2026). Failure to do so will result in liquidation and redemption of public shares.
- Financing Needs: The Company may need to obtain additional financing to complete a Business Combination or cover working capital deficiencies. The Sponsor has the option to provide "Working Capital Loans" (up to $1.5 million convertible to warrants), though none were outstanding as of March 31, 2025.
- Geopolitical Risks: The filing notes risks associated with global market volatility due to the Russia-Ukraine conflict and the Israel-Hamas conflict, which could impact the search for a target or the target's operations.
- Deferred Fees: A deferred underwriting fee of $6,037,500 is payable only upon the successful completion of a Business Combination.
Investor Verification Checklist
- Liquidity Runway: Verify if the $206,600 cash balance is sufficient to fund the search for a target through the June 2026 deadline without additional Sponsor loans.
- Redemption Value: Confirm the current redemption price per share ($10.21) and the potential for further accretion based on interest rates.
- Target Search Progress: Assess if the Company has identified any potential targets, given the 18-month deadline.
- Related Party Transactions: Review the $10,000/month administrative fee to the Sponsor and the $20,833/month consulting fee to the CFO for sustainability.
- Warrant Terms: Note that Public Warrants are exercisable at $11.50 per share and become exercisable 30 days after a Business Combination.